Quick Answer
IGC Pharma, Inc. reported Cash And Cash Equivalents At Carrying Value of $405.0 thousand for the year ending 2025.
- IGC Pharma, Inc. showed a decrease of -66.2% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from IGC Pharma, Inc.'s annual report (Form 10-K), filed with the SEC on June 27, 2025.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2010: $842.9 thousand | Q2 2010: $602.3 thousand | Q4 2010: $1.47 million | Q2 2011: $1.18 million | Q3 2011: $766.8 thousand | Q4 2011: $4.44 million | Q2 2012: $719.4 thousand | Q3 2012: $611.3 thousand | Q4 2012: $2.11 million | Q2 2013: $651.5 thousand | Q3 2013: $726.8 thousand | Q4 2013: $440.6 thousand | Q2 2014: $2.95 million | Q3 2014: $1.35 million | Q4 2014: $1.12 million | Q2 2015: $659.6 thousand | Q3 2015: $637.9 thousand | Q4 2015: $608.0 thousand | Q2 2016: $1.33 million | Q3 2016: $939.3 thousand | Q4 2016: $744.1 thousand | Q2 2017: $345.6 thousand | Q3 2017: $597.0 thousand | Q4 2017: $1.69 million | Q2 2018: $1.02 million | Q3 2018: $6.41 million | Q4 2018: $27.03 million | Q2 2019: $16.55 million | Q3 2019: $14.06 million | Q4 2019: $10.13 million | Q1 2020: $7.26 million | Q2 2020: $2.70 million | Q3 2020: $1.15 million | Q4 2020: $968.0 thousand | Q2 2021: $13.32 million | Q3 2021: $14.40 million | Q4 2021: $11.94 million | Q2 2022: $8.05 million | Q3 2022: $6.62 million | Q4 2022: $4.95 million | Q2 2023: $1.72 million | Q3 2023: $3.03 million | Q4 2023: $1.38 million | Q2 2024: $1.82 million | Q3 2024: $1.55 million | Q4 2024: $470.0 thousand | Q1 2025: $405.0 thousand | Q2 2025: $454.0 thousand | Q3 2025: $1.11 million.
- Over the full 16 years of available data (2010 to 2025), IGC Pharma, Inc.'s Cash And Cash Equivalents At Carrying Value has declined by 52.0%.
- Historical annual values: Fiscal year 2025: $405.0 thousand | Fiscal year 2024: $1.20 million | Fiscal year 2023: $3.20 million | Fiscal year 2022: $10.46 million | Fiscal year 2021: $14.55 million | Fiscal year 2020: $7.26 million | Fiscal year 2019: $25.61 million | Fiscal year 2018: $1.66 million | Fiscal year 2017: $538.0 thousand | Fiscal year 2016: $1.49 million | Fiscal year 2015: $824.5 thousand | Fiscal year 2014: $1.03 million | Fiscal year 2013: $1.06 million | Fiscal year 2012: $562.9 thousand | Fiscal year 2011: $1.58 million | Fiscal year 2010: $842.9 thousand.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: